上實城市開發(00563.HK)附屬與上海醫藥股份訂立項目管理服務協議
格隆匯5月26日丨上實城市開發(00563.HK)宣佈,於2021年5月26日,在上海醫藥股份委任的一家競標代理完成舉行招標程序後,公司全資附屬公司上實城開上海建設與上海醫藥股份訂立項目管理服務協議。根據項目管理服務協議,上實城開上海建設同意就該項目向上海醫藥股份提供項目管理服務,管理費總額為人民幣480萬元。
該項目由上海醫藥科技發起,上海醫藥科技建議建設一個綠色製藥精品生產基地,以安置上海醫藥股份遷移的部分現有生產設施,並供上海醫藥股份進一步擴展研發及產能。上海醫藥科技已在上海金山第二工業區物色一個總面積約52,352平方米的地盤,用作開發生產基地。上海醫藥科技目前計劃分兩期開發生產基地,而該項目(為項目管理服務協議的標的)即與生產基地第一期有關。預計該項目將涉及總面積約50,372平方米的建設。開發及建設該項目所需的全部資金由上海醫藥科技負責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.